Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 7/20 | 0.83 |
| ▸ | PFKFB3 | Q16875 | 9/20 | 0.64 |
| ▸ | PFKFB4 | Q16877 | 7/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463658 | 0.92 | CMA1 (0.83) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL2912913 | 0.91 | CMA1 (1.00) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL5621524 | 0.85 | PFKFB3 (0.70) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL2912893 | 0.83 | CMA1 (0.82) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL5620427 | 0.82 | CMA1 (0.85) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL16775639 | 0.82 | CMA1 (0.67) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL5621758 | 0.80 | PFKFB3 (0.80) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL788108 | 0.79 | PFKFB4 (1.00) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL17613337 | 0.78 | PFKFB3 (0.63) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 | |
| SCHEMBL5230241 | 0.77 | NPSR1 (0.67) | CMA1PFKFB3PFKFB4NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | REN, SERPINB1, CMA1 | CMA1 3/4885PFKFB3 3296/4885PFKFB4 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.